The company has had a ‘very strong’ third quarter in spite of a sharp decline in its HIV portfolio due to generic competition
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.